Thyrocare Technologies has released data on fever cases in India based on testing conducted between 2023 and 2025. The analysis includes 108,324 individuals who underwent comprehensive fever package testing across the country. The findings show that nearly one in three individuals tested were diagnosed with infections including dengue, typhoid, malaria, chikungunya and leptospirosis.
The data indicates that typhoid was the most detected infection, identified in 18.1 per cent of patients, followed by dengue at 14.4 per cent. Malaria, chikungunya and leptospirosis were also recorded across the testing population.
The analysis shows that nearly 10 per cent of infection-positive individuals had co-infections, with dengue and typhoid being the most common combination. The presence of co-infections was noted as a factor in diagnosis and treatment decisions.
Rahul Guha, MD and CEO, Thyrocare, said, “Recognising fever as a critical signal empowers patients and clinicians alike to act decisively. It shifts care from reactive treatment to timely and informed intervention. Ultimately, early evaluation, supported by data-driven insights, remains one of the most effective ways to navigate India’s evolving and unpredictable infectious disease landscape.”
Dr Preet Kaur, Chief Scientific Officer, Thyrocare, said, “Data from 2023 to 2025 shows that a significant number of patients carry serious infections, sometimes more than one at a time, revealing patterns that simple assumptions cannot capture. Beyond the visible rise in temperature, laboratory markers highlight hidden stress on organs, from drops in platelet counts to elevated liver enzymes, underscoring that fever is a systemic signal, not an isolated event.”
The study tracked infection trends over the three-year period. Dengue positivity declined, while malaria increased from 0.5 per cent to 1.1 per cent. Typhoid and chikungunya increased in 2024 and declined in 2025 but remained present across the testing population. Regional variation in infection rates was observed, with some areas reporting higher positivity rates.
Laboratory findings showed systemic impact in fever patients. Low platelet levels were observed in 27 per cent of fever patients compared to 15 per cent in non-fever cases. In malaria-positive patients, nearly 80 per cent experienced platelet reduction. Dengue-positive patients showed platelet reduction in 37 per cent of cases compared to 15 per cent in dengue-negative individuals.
Elevated liver enzyme levels were also recorded. Among fever patients, 56 per cent showed elevated SGOT and 37 per cent showed elevated SGPT, compared to 42 per cent and 26 per cent respectively in non-fever individuals.
Gender-based differences were recorded, with overall fever positivity higher among females at 32 per cent compared to 29 per cent in males. Typhoid detection was higher among females, while malaria was higher among males at 1.1 per cent compared to 0.5 per cent in females.
Seasonal patterns showed dengue positivity rising through the year and peaking around October. Malaria cases increased during monsoon months between May and September. Chikungunya increased in 2024 and declined in 2025, while typhoid declined across the three-year period.
The study also analysed standalone testing across 2.59 lakh patients between 2023 and 2025, recording a positivity rate of 22.6 per cent. Dengue accounted for 1.44 lakh tests with a positivity rate of 16.6 per cent, while typhoid recorded 1.15 lakh tests with a positivity rate of 22.7 per cent. Malaria had a positivity rate of 1.6 per cent across more than 90,000 tests, and chikungunya showed a positivity rate of 23 per cent across 27.9 thousand tests.
The findings indicate that comprehensive testing can identify multiple infections and provide clinical data in fever cases.